M367 Pill Identification: Clinical Efficacy, Toxicity Risks, and Opioid Dependency

The M367 pill is a high-potency prescription analgesic combining 10 mg of hydrocodone bitartrate and 325 mg of acetaminophen. 

While clinically indicated for the management of moderate to severe acute pain, its status as a Schedule II controlled substance underscores a profound potential for physical dependence and psychological addiction. 

In the clinical landscape, M367 represents the highest standard dosage for immediate-release hydrocodone combination products, marketed under the brand name Norco.

Poison‑center and epidemiologic data show that hydrocodone‑containing products were involved in thousands of abuse/misuse cases annually before rescheduling; after the 2014 reclassification of hydrocodone combination products (HCPs) to Schedule II, misuse/abuse case rates dropped by roughly 38-39%, though heroin‑related cases rose, according to Karami et al. 2024 in the paper “ The Impact of Hydrocodone Rescheduling on Utilization, Abuse, Misuse, and Overdose Deaths.”

Highlights

• Hydrocodone binds to mu-opioid receptors to alter pain perception, while acetaminophen inhibits prostaglandin synthesis to increase the pain threshold.
• M367 is the strongest common variant in its class, containing substantially more opioid content than the M365 (5 mg) or M366 (7.5 mg) counterparts.
• The acetaminophen component carries a strict 4,000 mg daily limit; exceeding this via M367 misuse aggravates acute liver failure or hepatic necrosis.
• As a Central Nervous System (CNS) depressant, M367 causes life-threatening respiratory depression, especially when combined with alcohol or benzodiazepines.
• Beyond physical “cravings,” M367 misuse sparks “mental clouding” and a total prioritization of the drug over vocational and social obligations.
• In 2022 NSDUH data, about 36.5 million people aged 12+ reported using hydrocodone products in the past year; of these, 10.2% (≈3.7 million) reported misuse (use not as directed, without a prescription, et cetera).

What Is the M367 Pill, and How Is It identified?

The M367 pill is a white, capsule-shaped (oblong) tablet produced by manufacturers like Mallinckrodt and Amneal Pharmaceuticals. The drug is easily identified by the “M367” debossed imprint on one side and a single bisecting score line on the reverse, which allows the tablet to be split for dosage adjustments. 

Clinically, it is classified as a semi-synthetic opioid blend, utilized primarily when non-opioid alternatives, such as NSAIDs or standalone acetaminophen, fail to provide adequate relief for post-surgical or injury-related trauma.

In the pharmaceutical market, M367 is the generic equivalent of Norco 10/325. It has largely replaced older formulations like Vicodin, which contained higher ratios of acetaminophen (500 mg or more). 

The FDA mandated this shift to lower the incidence of accidental liver toxicity. Because the hydrocodone content remains high, the “street value” and recreational appeal of the M367 imprint remain considerable among those seeking a euphoric CNS “high.”

What Are the Clinical Risks of Hydrocodone and Acetaminophen?

The primary clinical risk of M367 lies in its “hidden” toxicity—specifically the acetaminophen component. While users focus on the opioid “high,” the accumulation of acetaminophen in the liver is fatal before the user even realizes they are overdosing.

If a person takes more than 12 tablets in 24 hours, they surpass the 4,000 mg safety threshold, potentially triggering permanent liver cell death. This risk is compounded if the individual is also taking “hidden” acetaminophen found in over-the-counter flu or sleep medications.

From a neurological perspective, the hydrocodone in M367 poses a severe risk of secondary hyperalgesia, where long-term use actually makes the body more sensitive to pain. This creates a dangerous feedback loop: the patient experiences more pain as the drug wears off, leading them to take higher doses (tolerance), which in turn further desensitizes their natural pain-management systems. This cycle is the physiological foundation of opioid use disorder (OUD) and necessitates professional medical intervention to break.

How Does M367 Dependency Manifest?

Dependency on M367 begins subtly as a “psychic dependence,” where the individual feels they cannot face daily stressors or physical discomfort without the emotional “numbing” effect of the drug. Unlike other substances, M367 addiction is regularly characterized by “doctor shopping” or the falsification of pain symptoms to maintain a steady supply. Behavioral signs of escalating dependency include:

• Dosage Escalation: Taking two or three pills at once because the original single-pill dose no longer produces euphoria.
• Preoccupation: Spending significant mental energy tracking the remaining pill count or planning the next refill.
• Altered Administration: Crushing or snorting the tablets to bypass the digestive system for a faster “hit,” which substantially raises the risk of fatal overdose.
• Withdrawal Avoidance: Continuing to take M367 solely to avoid the “flu-like” agony of opioid withdrawal, rather than for actual pain management.
• Social Erosion: Withdrawing from family activities or hobbies in favor of the lethargy and “nodding out” associated with high-dose opioid use.

Because M367 is a CNS depressant, chronic misuse also takes a toll on the cardiovascular and respiratory systems. Users often experience “shallow breathing” episodes and a dangerously low heart rate (bradycardia). 

Over time, this lack of oxygen saturation exacerbates cognitive decline, memory impairment, and a permanent dampening of the brain’s natural ability to experience pleasure without chemical stimulation.

What Happens During M367 Withdrawal?

Opioid withdrawal from M367 is notoriously difficult and is the primary reason many individuals fail to quit “cold turkey.” 

Symptoms start within 6 to 12 hours of the last dose as the hydrocodone clears the bloodstream. The initial phase is marked by intense anxiety, muscle aches, and “lacrimation” (excessive tearing and runny nose). As the withdrawal progresses, the body enters a state of hyper-arousal, precipitating insomnia, profuse sweating, and severe gastrointestinal distress, inclusie of vomiting and diarrhea.

M367 withdrawal is rarely life-threatening on its own; the psychological despair and physical exhaustion bring about a “relapse overdose,” where the individual takes a high dose to stop the pain, but their lowered tolerance provokes respiratory failure. This is why medically supervised detox is the clinical gold standard. In a professional setting, clinicians utilize medications like Buprenorphine or Clonidine to stabilize the brain’s receptors and mitigate the “lightning-bolt” nerve pain associated with the detox process.

Is M367 stronger than Vicodin or Lortab?

Technically, M367 is the specific imprint for the 10 mg/325 mg dosage, which is the strongest version of what people commonly refer to as Vicodin or Lortab. The name “Vicodin” is used as a catch-all term; many Vicodin pills actually have less hydrocodone (5 mg or 7.5 mg). Therefore, if someone switches from a lower-strength “Vike” to an M367, the risk of accidental overdose is higher because the opioid concentration is much denser.

It is also important to distinguish M367 from “pure” hydrocodone products like Zohydro ER. M367 is an immediate-release medication, meaning the full 10 mg of hydrocodone hits the system at once. This “rapid onset” is what makes the M367 imprint particularly addictive relative to extended-release versions, as the brain quickly associates the act of swallowing the pill with an immediate surge of dopamine and pain relief.

Conclusion

The M367 pill is a potent medical tool that carries a heavy burden of risk. Its combination of high-dose hydrocodone and liver-taxing acetaminophen makes it a double-edged sword in pain management. For those who find themselves trapped in a cycle of M367 misuse, recognizing the transition from “pain relief” to “chemical necessity” is the first step toward safety. Professional addiction treatment remains the most effective pathway to navigating the complexities of opioid dependency and preventing the catastrophic consequences of long-term misuse.

Rediscover Life at Valley Spring Recovery Center

Get the compassionate support you deserve. We're here to help you reclaim joy, wellness, and a brighter future.

Verify Benefits

References

Karami, S., Kim, H. S., Majumder, S., & Alexander, G. C. (2024). The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths. Journal of Pain and Symptom Management.

National Institute on Drug Abuse. (2024). Opioids: Prescription pain medications. U.S. Department of Health and Human Services, National Institutes of Health.

Substance Abuse and Mental Health Services Administration. (2024). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2024). Acetaminophen: Avoiding liver injury. https://www.fda.gov/consumers/consumer-updates/acetaminophen-avoiding-liver-injury